DalsnaFinance

Celldex Therapeutics Inc $CLDX

Health Care

Russell 2000 New Jersey
Create a scorecard
$28.97
-0.40 (-1.36%)
As of Oct 22, 2026, 9:33 PM EDT
Price history
Loading chart…

Celldex Therapeutics Inc (CLDX) is trading down at $28.97 (-1.36%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.

Celldex Therapeutics Inc revenue & net income history (FY2016–FY2025)

RevenueNet incomeNet margin (right axis, %)
$12.7M−$123.0M−$258.8MFY2016 revenue: $6.79MFY2016 net income: −$128.5M · Net margin −1894.0%'16FY2017 revenue: $12.7MFY2017 net income: −$93.0M · Net margin −730.1%'17FY2018 revenue: $9.54MFY2018 net income: −$151.2M · Net margin −1585.1%'18FY2019 revenue: $3.57MFY2019 net income: −$50.9M · Net margin −1424.0%'19FY2020 revenue: $7.42MFY2020 net income: −$59.8M · Net margin −805.9%'20FY2021 revenue: $4.65MFY2021 net income: −$70.5M · Net margin −1516.0%'21FY2022 revenue: $2.36MFY2022 net income: −$112.3M · Net margin −4765.6%'22FY2023 revenue: $6.88MFY2023 net income: −$141.4M · Net margin −2054.8%'23FY2024 revenue: $7.02MFY2024 net income: −$157.9M · Net margin −2248.8%'24FY2025 revenue: $1.54MFY2025 net income: −$258.8M · Net margin −16748.0%'25−100%−75%−50%−25%0%FY2016 net margin: −1894.0% (off the scale, which stops at −100.0%)FY2017 net margin: −730.1% (off the scale, which stops at −100.0%)FY2018 net margin: −1585.1% (off the scale, which stops at −100.0%)FY2019 net margin: −1424.0% (off the scale, which stops at −100.0%)FY2020 net margin: −805.9% (off the scale, which stops at −100.0%)FY2021 net margin: −1516.0% (off the scale, which stops at −100.0%)FY2022 net margin: −4765.6% (off the scale, which stops at −100.0%)FY2023 net margin: −2054.8% (off the scale, which stops at −100.0%)FY2024 net margin: −2248.8% (off the scale, which stops at −100.0%)FY2025 net margin: −16748.0% (off the scale, which stops at −100.0%)
Celldex Therapeutics Inc annual financial statements
FY2016Dec 2016FY2017Dec 2017FY2018Dec 2018FY2019Dec 2019FY2020Dec 2020FY2021Dec 2021FY2022Dec 2022FY2023Dec 2023FY2024Dec 2024FY2025Dec 2025
Income statement
Revenue$6.79M$12.7M$9.54M$3.57M$7.42M$4.65M$2.36M$6.88M$7.02M$1.54M
Growth (year over year)+23.8%+87.8%−25.2%−62.5%+107.6%−37.3%−49.3%+192.0%+2.0%−78.0%
Gross profit$5.19M$12.0M$8.84M$3.47M$7.22M$4.55M$2.26M$6.58M$6.82M$1.34M
Gross margin76.4%94.5%92.7%97.2%97.3%97.8%95.8%95.6%97.2%87.1%
Operating income−$132.9M−$121.5M−$156.4M−$55.0M−$63.4M−$71.2M−$115.2M−$154.5M−$195.1M−$287.4M
Operating margin−1958.7%−953.7%−1640.1%−1540.2%−854.1%−1531.8%−4889.0%−2245.3%−2778.9%−18599.8%
Net income−$128.5M−$93.0M−$151.2M−$50.9M−$59.8M−$70.5M−$112.3M−$141.4M−$157.9M−$258.8M
Net margin−1894.0%−730.1%−1585.1%−1424.0%−805.9%−1516.0%−4765.6%−2054.8%−2248.8%−16748.0%
EPS (diluted)−$18.99−$10.86−$14.48−$3.51−$2.02−$1.64−$2.40−$2.92−$2.45−$3.90
Balance sheet
Cash and equivalents$42.5M$40.3M$24.3M$11.2M$43.8M$39.1M$29.4M$34.8M$28.4M$28.9M
Total assets$383.4M$315.6M$155.8M$122.9M$235.8M$444.7M$352.7M$465.6M$792.3M$583.0M
Total liabilities$117.9M$79.3M$31.7M$28.9M$26.5M$25.2M$26.5M$36.5M$45.3M$55.8M
Shareholders' equity$265.4M$236.4M$124.1M$94.0M$209.4M$419.5M$326.2M$429.2M$747.0M$527.2M
Cash flow
Operating cash flow−$113.0M−$99.9M−$75.2M−$46.4M−$40.4M−$60.9M−$103.7M−$107.3M−$157.8M−$210.9M
Capital expenditure$2.75M$1.79M$813.0K$731.0K$1.55M$1.25M$1.83M$1.82M$1.92M$2.71M
Free cash flow−$115.8M−$101.7M−$76.0M−$47.1M−$42.0M−$62.2M−$105.6M−$109.1M−$159.7M−$213.7M

From Celldex Therapeutics Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →

About Celldex Therapeutics Inc

Headquarters
Hampton, New Jersey From SEC filings, Oct 2026

Recent News (1)

More Health Care stocks

Browse all companies →